ReviewWorld journal of gastroenterology2015
Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 67 citations in OpenAlex.
- Antiviral therapy and the risk of extrahepatic malignancies in chronic hepatitis C: insights from recent evidence.Translational cancer research · 2026Article
- Potential utility of postmortem CT-based classification as a practical pre-autopsy assessment tool for hepatic steatosis.Scientific reports · 2026Article
- Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.Frontiers in immunology · 2026Article
- Bridging dimensions: a comparative analysis of 2D and 3D in vitro models for hepatocellular carcinoma research.Archives of toxicology · 2025Article
- Article
- Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007-2020.Journal of health, population, and nutrition · 2025Article
- Yogurt Supplementation Can Ameliorate Fatty Liver Diseases and Metabolic Syndrome in High Fat-Induced Conditions in Mice.Food science & nutrition · 2025Article
- A double-blind, randomized control trial to investigate the therapeutic potential of garlic scapes for high apoprotein E levels in a high-Fat diet-induced hypercholesteremic rat model.Food science & nutrition · 2024Article
- NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care.Internal and emergency medicine · 2023Review
- Oxidative stress in Wernicke's encephalopathy.Frontiers in aging neuroscience · 2023Review
- Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences.International journal of molecular sciences · 2022Review
- Chronic inflammation, cancer development and immunotherapy.Frontiers in pharmacology · 2022Review
- NAFLD and HBV interplay - related mechanisms underlying liver disease progression.Frontiers in immunology · 2022Review
- MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3.Frontiers in physiology · 2022Article
- Inhibition of autophagy impairs free fatty acid-induced excessive lipid accumulation in hepatocellular carcinoma and hepatic cells.Journal of biosciences · 2022Article
- Role of Insulin Resistance in MAFLD.International journal of molecular sciences · 2021Review
- Fat and fibrosis as confounding cofactors in viscoelastic measurements of the liver.Physics in medicine and biology · 2021Article
- Article
- Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.World journal of gastroenterology · 2021Article
- The effect of hydroalcoholic Berberis integerrima fruits extract on the lipid profile, antioxidant parameters and liver and kidney function tests in patients with nonalcoholic fatty liver disease.Saudi journal of biological sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) is globally increasing and has become a world-wide health problem. Chronic infection with hepatitis B virus or hepatitis C virus (HCV) is associated with hepatic steatosis. Viral hepatitis-associated hepatic steatosis is often caused by metabolic syndrome including obesity, type 2 diabetes mellitus and/or dyslipidemia. It has been reported that HCV genotype 3 exerts direct metabolic effects that lead to hepatic steatosis. In this review, the differences between NAFLD/NASH and viral hepatitis-associated steatosis are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.